High levels of KLK7 protein expression are related to a favorable prognosis in triple-negative breast cancer patients.
KLK7
Triple-negative breast cancer
clinical relevance
kallikrein-related peptidase
prognostic marker
Journal
American journal of cancer research
ISSN: 2156-6976
Titre abrégé: Am J Cancer Res
Pays: United States
ID NLM: 101549944
Informations de publication
Date de publication:
2020
2020
Historique:
received:
03
05
2020
accepted:
12
05
2020
entrez:
10
7
2020
pubmed:
10
7
2020
medline:
10
7
2020
Statut:
epublish
Résumé
In normal physiology, kallikrein-related peptidase 7 (KLK7), together with other members of the kallikrein-related peptidase family, is mainly involved in skin desquamation and keratinization processes. Moreover, expression of KLK7 was shown in various tumor types to be dysregulated and to correlate to patients' survival time. However, there are contradictory reports in breast cancer whether KLK7 represents an unfavorable or favorable prognostic biomarker. In the present study, we examined the prognostic value of KLK7 protein expression in triple-negative breast cancer (TNBC), determined by immunohistochemistry (IHC). A cohort encompassing 133 TNBC specimens, present on tissue microarrays, was analyzed. For quantification of the staining intensity, an automated digital IHC image analysis algorithm was applied. In both Kaplan-Meier and univariate Cox analyses, elevated KLK7 protein levels were significantly linked with prolonged overall survival (OS). In multivariable Cox analysis, addition of KLK7 immunoreactivity scores to the base model (including the clinical parameters age, tumor size, and nodal status) demonstrated that KLK7 protein expression remained as a statistically significant, independent parameter for prolonged OS. These results strongly indicate that KLK7 is a favorable prognostic biomarker in triple-negative breast cancer.
Types de publication
Journal Article
Langues
eng
Pagination
1785-1792Informations de copyright
AJCR Copyright © 2020.
Déclaration de conflit d'intérêts
None.
Références
J Dermatol Sci. 2019 Aug;95(2):50-55
pubmed: 31279501
J Ovarian Res. 2014 Dec 05;7:109
pubmed: 25477184
Clin Exp Med. 2018 May;18(2):203-213
pubmed: 29435805
Heliyon. 2017 Jul 17;3(7):e00356
pubmed: 28761938
Gene. 2000 Aug 22;254(1-2):119-28
pubmed: 10974542
Am J Cancer Res. 2018 Sep 01;8(9):1856-1864
pubmed: 30323977
Biol Chem. 2017 Sep 26;398(10):1151-1164
pubmed: 28755528
J Biol Chem. 2015 Jul 17;290(29):17762-75
pubmed: 26032414
Lancet. 2017 Mar 18;389(10074):1134-1150
pubmed: 27865536
Cancer Epidemiol Biomarkers Prev. 2012 Jul;21(7):1135-42
pubmed: 22573795
Thromb Haemost. 2009 Apr;101(4):741-7
pubmed: 19350120
Thromb Haemost. 2004 Jan;91(1):180-6
pubmed: 14691584
Cancer. 2007 May 1;109(9):1811-20
pubmed: 17354228
Oncol Lett. 2015 Jan;9(1):418-424
pubmed: 25436002
Cancer Res. 2010 Apr 1;70(7):2624-33
pubmed: 20332224
Biol Chem. 2018 Sep 25;399(9):1099-1105
pubmed: 29498930
Mol Oncol. 2017 Oct;11(10):1330-1347
pubmed: 28636767
Ann Surg Oncol. 2010 Nov;17(11):3037-42
pubmed: 20544292
Br J Cancer. 2018 Oct;119(7):1-9
pubmed: 30287916
Ann Oncol. 2009 Dec;20(12):1913-27
pubmed: 19901010
Innate Immun. 2015 Aug;21(6):575-86
pubmed: 25563717
Biol Chem. 2012 Apr;393(5):391-401
pubmed: 22505521
Radiol Oncol. 2013 Oct 08;47(4):319-29
pubmed: 24294176
N Engl J Med. 2010 Nov 11;363(20):1938-48
pubmed: 21067385
Crit Rev Clin Lab Sci. 2016 Aug;53(4):277-91
pubmed: 26886390
Clin Biochem. 2003 Mar;36(2):135-43
pubmed: 12633763
Cancer Sci. 2009 Apr;100(4):601-7
pubmed: 19453546
Biol Chem. 2016 Nov 1;397(11):1135-1146
pubmed: 27279059
Clin Chem. 2006 Jun;52(6):1070-9
pubmed: 16627559
Mol Cell Proteomics. 2019 May;18(5):818-836
pubmed: 30705123
Biol Chem. 2018 Sep 25;399(9):959-971
pubmed: 29604204
CA Cancer J Clin. 2014 Jan-Feb;64(1):52-62
pubmed: 24114568
Biol Chem. 2018 Sep 25;399(9):937-957
pubmed: 29885274
Expert Opin Ther Targets. 2018 Sep;22(9):745-763
pubmed: 30114962
Breast Cancer Res Treat. 2015 Jul;152(2):323-36
pubmed: 26099606
Clin Chem. 2006 Oct;52(10):1879-86
pubmed: 16916986
Biol Chem. 2014 Jan;395(1):95-107
pubmed: 23999494